See more : Enauta Participações S.A. (ENAT3.SA) Income Statement Analysis – Financial Results
Complete financial analysis of Rezolute, Inc. (RZLT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rezolute, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Alicon Castalloy Limited (ALICON.BO) Income Statement Analysis – Financial Results
- Graph Blockchain Inc. (REGRD) Income Statement Analysis – Financial Results
- ECN Capital Corp. (ECN.TO) Income Statement Analysis – Financial Results
- PFA Invest Balance B (PFIBAB.CO) Income Statement Analysis – Financial Results
- Avertronics Inc. (3597.TWO) Income Statement Analysis – Financial Results
Rezolute, Inc. (RZLT)
About Rezolute, Inc.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 36.00K | 382.00K | 256.00K | 303.00K | 18.00K | 48.00K | 1.07M | 12.57M | 8.27M | 5.85M | 2.40M | 4.56M | 4.84K |
| Gross Profit | -36.00K | -382.00K | -256.00K | -303.00K | -18.00K | -48.00K | -1.07M | -12.57M | -8.27M | -5.85M | -2.40M | -4.56M | -4.84K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 55.74M | 43.81M | 32.49M | 14.99M | 14.45M | 19.08M | 17.28M | 12.09M | 9.45M | 4.70M | 34.32K | 3.49K | 0.00 |
| General & Administrative | 196.00K | 12.18M | 9.36M | 7.91M | 6.07M | 6.82M | 9.10M | 8.23M | 5.50M | 6.00M | 5.13M | 6.10M | 42.67M |
| Selling & Marketing | 14.45M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -42.63M |
| SG&A | 14.64M | 12.18M | 9.36M | 7.91M | 6.07M | 6.82M | 9.10M | 8.23M | 5.50M | 6.00M | 5.13M | 6.10M | 42.67K |
| Other Expenses | 0.00 | 0.00 | -231.00K | -515.00K | 0.00 | 321.00K | 136.13K | 37.14K | 5.33M | 3.51M | 11.30K | 295.00 | 6.62M |
| Operating Expenses | 70.42M | 55.99M | 41.61M | 22.38M | 20.52M | 25.90M | 26.38M | 20.32M | 14.95M | 10.70M | 5.18M | 6.11M | 42.67K |
| Cost & Expenses | 70.42M | 55.99M | 41.61M | 22.38M | 20.52M | 25.90M | 26.38M | 20.32M | 14.95M | 10.70M | 5.18M | 6.11M | 47.51K |
| Interest Income | 0.00 | 4.21M | 80.00K | 63.00K | 188.00K | 61.00K | 1.00K | 0.00 | 965.00 | 4.97K | 12.18K | 106.04K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 1.81M | 375.00K | 0.00 | 4.96M | 689.19K | 1.60K | 5.04K | 6.73K | 4.23M | 568.86K | 0.00 |
| Depreciation & Amortization | 36.00K | 382.00K | 256.00K | 303.00K | 18.00K | 48.00K | 1.07M | 1.11M | 751.25K | 134.13K | 11.30K | 295.00 | 221.00 |
| EBITDA | -68.42M | -51.41M | -41.83M | -22.88M | -20.32M | -25.44M | -28.11M | -19.16M | -14.18M | -11.22M | -5.49M | -6.16M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -70.42M | -55.99M | -41.84M | -22.89M | -20.52M | -25.94M | -28.73M | -20.32M | -14.95M | -10.70M | -5.18M | -6.11M | -45.73K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.96M | 4.20M | 783.00K | 1.99M | 188.00K | -4.50M | -1.13M | 46.92K | 15.75K | -664.48K | -4.55M | -620.58K | -1.78K |
| Income Before Tax | -68.46M | -51.79M | -41.06M | -20.90M | -20.33M | -30.45M | -29.86M | -20.28M | -14.94M | -11.36M | -9.73M | -6.73M | -47.51K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -137.90K | -2.28M | 375.00K | -297.00 | -29.00K | 2.93M | -11.37K | -19.82K | 662.72K | 336.49K | 157.76K | 3.56K |
| Net Income | -68.46M | -51.79M | -38.78M | -21.28M | -20.33M | -30.42M | -29.86M | -20.28M | -14.94M | -11.36M | -9.73M | -6.73M | -49.29K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.33 | -1.01 | -2.13 | -2.77 | -3.54 | -17.11 | -26.83 | -24.55 | -30.14 | -27.12 | -51.84 | -54.21 | -0.64 |
| EPS Diluted | -1.33 | -1.01 | -1.99 | -2.77 | -3.54 | -17.11 | -26.83 | -24.55 | -30.14 | -27.12 | -51.84 | -54.21 | -0.64 |
| Weighted Avg Shares Out | 51.47M | 51.19M | 18.20M | 7.67M | 5.75M | 1.78M | 1.11M | 825.93K | 495.46K | 419.00K | 187.69K | 124.09K | 77.35K |
| Weighted Avg Shares Out (Dil) | 51.47M | 51.19M | 19.49M | 7.67M | 5.75M | 1.78M | 1.11M | 825.93K | 495.46K | 419.00K | 187.69K | 124.09K | 77.35K |
Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism
REDWOOD CITY, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced results following administration of RZ358 to a patient with refractory hypoglycemia...
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023 Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023
Rezolute to Participate in Upcoming Investor Conferences in September
REDWOOD CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that Nevan Charles Elam, Chief...
Rezolute to Present at the Jefferies London Healthcare Conference
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced that Nevan Charles Elam,...
Rezolute, Inc. (RZLT) Upgraded to Buy: Here's Why
Rezolute, Inc. (RZLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rezolute (RZLT) Posts Positive Data From Congenital HI Study
Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism.
Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering
REDWOOD CITY, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced the pricing of an underwritten public...
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering
REDWOOD CITY, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced that it intends to offer and...
Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021
Continuous glucose monitoring reveals undertreated hypoglycemia in patients with congenital hyperinsulinism
Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress
REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the fourth quarter and fiscal full...
Source: https://incomestatements.info
Category: Stock Reports